Skip to content
DraconiticResearch
Search Sources API
182,544 studies31 sourcesUpdated 50 min ago
PreprintCC BYbioRxiv

Single-Sample Network Topology Unveils Pathogenic Hubs in Sjögren's Disease

  1. 1Federal University of Rio Grande do Norte

Abstract

Sjogren's disease (SD) is a systemic autoimmune condition characterized by extensive clinical and biological heterogeneity, complicating the development of targeted therapies. To better describe the personalized molecular rewiring driving SD pathogenesis, we utilized bulk RNA-sequencing data from whole blood samples of the PRECISESADS IMI consortium to construct sample-specific gene interaction networks by applying the LIONESS algorithm integrated with experimental protein-protein interaction evidence. Comparing SD patients against healthy controls, we identified an absolute total of 647 Differentially Interacting Genes (DIGs) representing structural shifts in network connectivity. Topological clustering of these DIGs revealed four major functional macro-modules underlying disease pathology: defense response to virus, B cell activation, DNA replication, and positive regulation of protein catabolic process. Central topological hubs, such as ISG15, OASL, UBE2L6, and LGALS3BP, were identified as drivers of this reorganization, a fact supported by integrating network topology with single-sample Gene Set Enrichment Analysis (ssGSEA), which demonstrated that the interaction degree of these hubs exhibits strong positive correlations with the functional activity of their respective pathogenic pathways. To translate these structural findings into therapeutic opportunities, we performed an in-silico network vulnerability analysis on patient-specific interaction networks, ranking targets by the fractional loss of global efficiency following their removal and correcting for node degree. This approach prioritised the receptor tyrosine kinase EPHB2, which has no prior description in this disease, alongside the kinase BLK and the B-cell co-receptor CD22, a target independently evaluated in a previous clinical trial in SD. Thus, our single-sample network framework provides a computational mechanism to uncover pathogenesis-related modules and to prioritise drug repurposing candidates in SD, while also recovering targets whose clinical failure bounds what network topology alone can predict.

Related

  1. Multi-stage single-cell atlas of a chordate non-embryonic development unveils dedifferentiating bud founder cells
    Marie Lebel, Solène Marchal, Tiphaine Sancerni +9
    Nature CommunicationsPeer-reviewedCC BY 4.0Full textDevelopmental biologyHAL
  2. Immunological cross-talk between periodontitis and systemic lupus erythematosus: the role of T–B cell dysregulation in the shared pathogenic network
    Weiwen Hu, Jianxiong Wang, Jingjing Tong +7
    Frontiers in immunologyPeer-reviewedCC BYFull textImmunologyEurope PMC
  3. Network topology reveals distinct forms of developmental leverage in the Drosophila wing
    L. Gardner, D. Adams, K. Z. McKenna
    bioRxivPreprintAll rights reservedFull textDevelopmental biologybioRxiv
  4. Stochasticity in Metabolism: Oxidative Stress Response Phenotypes As Emergent Consequences of Network Topology
    A. Mihnev, D. Luong, J. Porat +1
    bioRxivPreprintAll rights reservedFull textSystems & synthetic biologybioRxiv
  5. Non-coding RNAs drive transcriptional network rewiring underlying thermal dimorphism in a human pathogenic fungus
    X. Hu, J. Wang, E. Yang
    bioRxivPreprintCC BY-NC-NDFull textMicrobiologybioRxiv
BibTeX
@misc{cavalcante2026singlesample,
  title = {{Single-Sample Network Topology Unveils Pathogenic Hubs in Sjögren's Disease}},
  author = {J. V. Ferreira Cavalcante and R. J. Dalmolin and D. Marques-Coelho},
  howpublished = {bioRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.16.752113},
  url = {https://www.biorxiv.org/content/10.64898/2026.09.16.752113v1},
  note = {CC BY},
}
RIS
TY  - UNPB
TI  - Single-Sample Network Topology Unveils Pathogenic Hubs in Sjögren's Disease
AU  - J. V. Ferreira Cavalcante
AU  - R. J. Dalmolin
AU  - D. Marques-Coelho
PY  - 2026
DA  - 2026/09/16
PB  - bioRxiv
DO  - 10.64898/2026.09.16.752113
UR  - https://www.biorxiv.org/content/10.64898/2026.09.16.752113v1
AB  - Sjogren's disease (SD) is a systemic autoimmune condition characterized by extensive clinical and biological heterogeneity, complicating the development of targeted therapies. To better describe the personalized molecular rewiring driving SD pathogenesis, we utilized bulk RNA-sequencing data from whole blood samples of the PRECISESADS IMI consortium to construct sample-specific gene interaction networks by applying the LIONESS algorithm integrated with experimental protein-protein interaction evidence. Comparing SD patients against healthy controls, we identified an absolute total of 647 Differentially Interacting Genes (DIGs) representing structural shifts in network connectivity. Topological clustering of these DIGs revealed four major functional macro-modules underlying disease pathology: defense response to virus, B cell activation, DNA replication, and positive regulation of protein catabolic process. Central topological hubs, such as ISG15, OASL, UBE2L6, and LGALS3BP, were identified as drivers of this reorganization, a fact supported by integrating network topology with single-sample Gene Set Enrichment Analysis (ssGSEA), which demonstrated that the interaction degree of these hubs exhibits strong positive correlations with the functional activity of their respective pathogenic pathways. To translate these structural findings into therapeutic opportunities, we performed an in-silico network vulnerability analysis on patient-specific interaction networks, ranking targets by the fractional loss of global efficiency following their removal and correcting for node degree. This approach prioritised the receptor tyrosine kinase EPHB2, which has no prior description in this disease, alongside the kinase BLK and the B-cell co-receptor CD22, a target independently evaluated in a previous clinical trial in SD. Thus, our single-sample network framework provides a computational mechanism to uncover pathogenesis-related modules and to prioritise drug repurposing candidates in SD, while also recovering targets whose clinical failure bounds what network topology alone can predict.
ER  -